SCHEDULE 13G: Decheng Capital Entities and Xiangmin Cui Disclose Significant 6.1% Stake in Upstream Bio, Inc.

Decheng Capital Global Life Sciences Fund IV, L.P., Decheng Capital Global Healthcare Fund (Master), LP, and related entities, along with Xiangmin Cui, have disclosed beneficial ownership of 6.1% of Upstream Bio, Inc.'s common stock as of December 31, 2024.

Summary

• Decheng Capital Global Life Sciences Fund IV, L.P. (Fund IV) and Decheng Capital Global Healthcare Fund (Master), LP (Healthcare), along with their general partners and manager Xiangmin Cui, have filed a Schedule 13G disclosing their beneficial ownership in Upstream Bio, Inc.
• As of December 31, 2024, the reporting persons collectively beneficially own 3,285,293 shares of Upstream Bio, Inc. common stock.
• This aggregate ownership represents 6.1% of Upstream Bio, Inc.'s total outstanding common stock, based on 53,596,601 shares outstanding as of November 5, 2024, as reported in the Issuer's Quarterly Report on Form 10-Q.
• Fund IV directly holds 3,085,293 shares, representing 5.8% of the class.
• Healthcare directly holds 200,000 shares, representing 0.4% of the class.
• Xiangmin Cui, as the manager of Decheng Capital Management IV (Cayman), LLC (general partner of Fund IV) and indirect managing member and ultimate beneficial owner of Decheng Capital Global Healthcare GP, LLC (general partner of Healthcare), shares voting and investment authority over all 3,285,293 shares.

Sentiment

Score: 6

Explanation: Neutral to slightly positive. The filing itself is a factual disclosure of ownership, which is neutral. However, a significant stake by a specialized investment fund can be interpreted as a positive signal of confidence in the company's prospects, hence a slight positive lean.

Positives

• A significant beneficial ownership stake of 6.1% in Upstream Bio, Inc. by Decheng Capital entities and Xiangmin Cui indicates a notable investment position.
• The investment group, specializing in life sciences, has acquired a substantial holding, potentially signaling confidence in Upstream Bio, Inc.'s long-term prospects.

Future Outlook

NA

Industry Context

This filing indicates a significant investment by a specialized life sciences fund in Upstream Bio, Inc., a biotechnology company. Such investments are common in the biotech sector, where venture capital and specialized funds often take substantial early-stage or growth-stage positions to support drug development and innovation. Decheng Capital's focus on global life sciences suggests a strategic interest in the company's potential within the broader pharmaceutical and biotechnology landscape.

Stakeholder Impact

• Shareholders: Increased transparency regarding significant ownership stakes, potentially signaling investor confidence.
• Investors: Provides insight into institutional holdings and potential long-term investment interest in Upstream Bio, Inc.

Key Dates

Keywords

Upstream Bio Inc., Decheng Capital, Xiangmin Cui, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Biotechnology, Life Sciences Investment